Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086
Recruiting
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Digestive Health Specialists, Dothan, Alabama +196 locations
Conditions: Ulcerative Colitis, Obesity or Overweight
Register for Updates
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136
Recruiting
This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Chula Vista, California +183 locations
Conditions: Heterozygous Familial Hypercholesterolaemia
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
NCT06883305
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/22/2025
Locations: Research Site, Foley, Alabama +281 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of California - San Diego, La Jolla, California +75 locations
Conditions: Select Advanced Solid Tumors
Register for Updates
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Digestive Health Specialists, Dothan, Alabama +188 locations
Conditions: Crohn's Disease, Obesity or Overweight
Register for Updates
A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women
NCT07022925
Recruiting
The goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms via an app. The main question it aims to answer is: What is the accuracy of the developed algorithm from the investigational device compared to daily self-report via an app in characterizing perimenopausal symptoms? Participants will be asked to wear IndentifyHer's weara... Read More
Gender:
FEMALE
Ages:
Between 35 years and 55 years
Trial Updated:
07/22/2025
Locations: KGK Science Inc., London, Ontario
Conditions: Perimenopause, Perimenopausal Depression, Perimenopausal Insomnia, Perimenopausal Women, Menopausal Depression, Menopausal Hot Flashes, Menopausal and Postmenopausal Disorders, Menopausal Vasomotor Symptoms
Register for Updates
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505
Recruiting
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/22/2025
Locations: Rehabilitation & Neurological Services /ID# 270782, Huntsville, Alabama +40 locations
Conditions: Chronic Migraine
Register for Updates
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
07/22/2025
Locations: University of Arizona, Tucson, Arizona +77 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Register for Updates
RIC-NEC Randomized Controlled Trial
NCT05279664
Recruiting
Necrotizing enterocolitis (NEC) is a serious intestinal disease of preterm and term neonates which remains a major cause of intestinal failure, and an unsolved clinical challenge in pediatrics. While overall mortality of preterm infants continues to decrease due to improvements in general neonatal care, mortality caused by NEC remains high (up to 30-50%) and survivors suffer from reduced quality of life, and long-term disabilities such as debilitating complications of intestinal failure, poor gr... Read More
Gender:
ALL
Ages:
0 weeks and above
Trial Updated:
07/22/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio +3 locations
Conditions: Necrotizing Enterocolitis
Register for Updates
A Clinical Trial to Investigate the Effect of Pollen Extracts on Menopausal Symptoms in Healthy Women.
NCT06889753
Recruiting
The goal of this study is to investigate the effect of pollen extracts on menopausal symptoms in healthy women The main question it aims to answer is: What is the difference in change in severity of menopausal symptoms as assessed by the total Menopause Rating Scale (MRS) score from baseline at Week 36 between Graminex Water Soluble Pollen Extract (WSPE), Lipid Soluble Pollen Extract (LSPE), and Placebo? Participants will be asked to complete the MRS assessment tool to rate their menopausal sy... Read More
Gender:
FEMALE
Ages:
Between 45 years and 65 years
Trial Updated:
07/22/2025
Locations: KGK Science Inc., London, Ontario
Conditions: Menopausal Women
Register for Updates
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462
Recruiting
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/22/2025
Locations: Research Site, La Jolla, California +74 locations
Conditions: Ophthalmic Safety in Patients With Breast Cancer
Register for Updates
The Effect of Targeting the Plantaris Muscle-tendon in Surgical Correction of Ankle Equinus in Children
NCT07090057
Recruiting
Tight ankle muscles can produce ankle equinus (limited ability to pull the foot upward) and occur often in children, significantly impacting their ability to walk. If not treated, children with ankle equinus frequently experience reduced function and long-term foot problems, such as pain. Currently, treatment options include surgery or Botulinum toxin (BoNTA) injection into the large calf muscles that point the foot downwards, aiming to reduce their tightness. However, these treatments can be le... Read More
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
07/22/2025
Locations: Stollery Children's Hospital, Edmonton, Alberta
Conditions: Idiopathic Toe Walking, Cerebral Palsy, Hereditary Spastic Paraparesis, Traumatic Brain Injury, Spinal Cord Injury, Spinal Cord Tethering, Stroke, Hereditary Sensory-motor Neuropathy
Register for Updates